Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

NCT02269085 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Carfilzomib
BEHAVIORAL: Phone Calls

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]